Cancer Screening

Our proprietary miRNA technology detects cancer at its earliest, most treatable stages. With minimally invasive test and accurate insights, our tests enable patients to act sooner.

A pioneering blood test for the early detection of gastric (stomach) cancer.

LUNGClear

A minimally invasive blood test designed to identify lung cancer at an early stage.

Cancer Treatment Selection

We leverage advanced Next-Generation Sequencing (NGS) technology to empower patients in personalised cancer treatment selection.

APEX Tissue

A Targeted 50-Gene
Profiling Test

COMPASS Tissue

A Comprehensive 1021-Gene
Profiling Test

ID3EAL Suite

Our proprietary miRNA detection technology

MicroRNAs (miRNAs) are challenging to measure precisely because they are small, have a high degree of homology, and are present in low abundance in circulating samples. Mirxes addresses this difficulty with a unique three-primer approach designed to detect miRNA with high sensitivity, specificity, and robustness.

Discovery Solutions

Exceptional miRNA detection powered by the class-leading ID3EAL RT-qPCR technology

Gain Insights From The World’s Largest Clinical miRNA Database

0 +

SAMPLES RUN

0 +

SAMPLES IN THE PIPELINE

0 +

CANCER TYPES PROFILED

0 +

MAJOR PARTNERS

0 +

MAJOR HUMAN DISEASES PROFILED

Why microRNA

Important Gene Regulators

miRNAs are small endogenous non-coding RNAs of ~17-25 nucleotides in length conserved across various species. They are essential components of gene regulatory networks and regulate gene expression post-transcriptionally by repressing translation or by triggering the degradation of multiple-target mRNAs.

Multiple Disease Associations

miRNAs are involved in all crucial physiological processes including development, proliferation and differentiation, metabolism, homeostasis and host-viral interactions. Unsurprisingly, their aberrant expression has been implicated in a multitude of diseases, including cancer, cardiovascular, metabolic, neurodegenerative and infectious diseases.

Stability in Biofluids

miRNAs are secreted into circulation, exist stably and readily detected in various biofluids including serum, plasma, urine, saliva, tears and aqueous and vitreous humor.

Ideal for Liquid Biopsy

miRNAs are resistant to the effects of freeze-thaw cycles, large variations in pH and prolonged exposure to room temperature. All these abovementioned characteristics make them promising liquid biopsy biomarkers.

Wide Potential in Clinical Applications

Diagnostic and prognostic tests^1,2,5,6
Therapy Selection⁷
Treatment Monitoring¹
Disease Stratification⁴
Companion Diagnostics³

Benefits

Discovery Services

Comprehensive, end-to-end miRNA profiling and biomarker discovery services.

Research Tools

Power your basic and translational studies with miRNA profiling products that leverage the ID3EAL technology.

Early Access

Be an early adopter of the newest in our exciting product pipeline and enjoy having a part in shaping a product.

First

Second

Third

The ID3EAL Technology

The Problem

MicroRNAs (miRNAs) are notoriously difficult to quantify accurately due to their high degree of homology and small size. Their low abundance in circulation further aggravates this difficulty. Interestingly, increasing evidence shows that low abundant miRNA targets in biofluids carry diagnostic value for early detection of diseases.

Hence, there is mounting demand for improved detection and quantification methods, especially since their promise as novel diagnostic and prognostic biomarkers for multiple human diseases is just being realized.

The small size of microRNAs makes detection extremely difficult. Less than 100 miRNAs are robustly detected in biofluids.

Nat Methods. 2014 Aug;11(8):809-15.

Our Solution

A unique three primer approach for sensitivity, specificity and robustness.

Uniquely designed stem-loop primer minimizes generation of non-specific cDNA
MicroRNA-specific forward and reverse qPCR primers designed for robust amplification of intended target while preventing amplification of mismatched targets

Watch the animated walkthrough of our technology below

Mirxes miRNA qPCR technology

Mirxes, microRNA (miRNA), technology explained – in-depth version

Product Highlight

ID3EAL PanoramiR miRNA Knowledge Panel

Minimal Input, Maximum Insight.

The ID3EAL PanoramiR Knowledge Panel is an effective approach for profiling miRNAs important in biological processes, disease mechanisms, or biomarker discovery for clinical applications such as disease diagnosis and prognosis, disease stratification or treatment selection.

Our Technology powered by microRNA

Step 1

> 450 miRNAs Detectable in 200ul of Serum

Step 2

> 7 Log Dynamic Range

Step 3

Efficient Discrimination between homologs

Step 4

Consistent Performance for Difficult Templates

Step 5

Excellent Reproducibility

Step 6

Two Hour workflow for the entire process

References

¹Kahraman M. et al. MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer. Scientific Reports 2018; Vol.8, Article 11584.
²Reis P. et al. MicroRNAs as liquid biopsy biomarkers for early detection in lung cancer. Journal of Thoracic Oncology 2018; 13(10):S785-S786.
³Ji J. et al. Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in heptacocellular carcinoma. International Journal of Biological Sciences 2013; 9(3):303-12
⁴Fadaka AO. et al. Biomarkers for stratification in colorectal cancer: microRNAs. Cancer Control 2019; 26(1):1-11
⁵Wang J. et al. MicroRNA as biomarkers and diagnostics. Journal of Cellular Physiology 2015; 231(2):25-30.
⁶Yang J. et al. Expression analysis of microRNA as prognostic biomarkers in colorectal cancer. Oncotarget 2016; 8(32):52403-12.
⁷Chan HW. et al. A pilot study on microRNA profile in tear fluid to predict response to anti-VEGF treatments for diabetic macular edema. Journal of Clinical Medicine 2020; 9(9):2920

Key Disease Areas & Publications

¹GASTRIC CANCER Gut, 2020 – Profiling and analysis of 578 miRNA candidates to develop a cost-effective 12-miRNA serum biomarker assay for gastric cancer.
²LUNG CANCER PNAS, 2020 – Discovery, profiling and analysis of 35 miRNA candidates to develop a minimally invasive 5-miRNA serum biomarker test for detection of early stage non-small cell lung cancer.
³CARDIO- VASCULAR DISEASE J Am Coll Cardiol, 2019 – Combining an 8-microRNA panel with NT-proBNP to improve detection of non-acute heart failure.
⁴METABOLIC DISEASE Front Physiol, 2019 – Integrated analysis on plasma proteins and microRNAs leading to nomination of protein markers and microRNA post-translational regulatory sites.